share_log

Oppenheimer Maintains Outperform on Chemed, Lowers Price Target to $590

Benzinga ·  Jul 27, 2023 10:12

Oppenheimer analyst Michael Wiederhorn maintains Chemed (NYSE:CHE) with a Outperform and lowers the price target from $610 to $590.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment